Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Edaravone Bioavailability Study in Healthy Subjects
NCT04776135Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edaravone in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Area Under the Concentration Versus Time Curve, Maximum Plasma Concentration and 7 more. Started Feb 2021; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04776135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776135.